Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Invitation to Nanoform’s Q4 and FY 2023 Report Presentation

Press release Nanoform Finland Plc February 16, 2024 11:00 a.m. Finnish time / 10:00 a.m. Swedish time Invitation to Nanoform’s Q4 and FY 2023 Report Presentation Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, will publish its Q4 and FY 2023 report on February 29, 2024, at 8.10 a.m. Finnish time / 7.10 a.m. Swedish time. The company will hold an online presentation and conference call the same day at 3.00 p.m. Finnish time / 2.00 p.m. Swedish time. Nanoform will be represented by CEO Edward Hæggström, CFO Albert Hæggström

United Bankers Plc’s Financial Statements Bulletin 2023: Record profit supported by new strategic funds

United Bankers Plc’s Financial Statements Bulletin 2023: Record profit supported by new strategic fundsJanuary-December 2023 in brief · The Group’s revenue (income from operations) in the financial period amounted to EUR 52.1 million (EUR 48.6 million in 1–12/2022). · The Group’s adjusted EBITDA amounted to EUR 19.1 million (EUR 18.5 million in 1–12/2022) and adjusted operating profit to EUR 16.9 million (EUR 16.6 million in 1–12/2022). · The profit for the financial period amounted to EUR 13.8 million (EUR 12.9 million in 1–12/2022). · Earnings per share were EUR 1.24 (EUR 1.

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 37 – 16 FEBRUARY 2024  In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 30/24 and 31/24.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Stig Frederiksen, Head of Communications & Investor Relations, tel.: +45 32 71 08 55, e-mail: sfr@norden.com

Nomination Committee Board Proposals for 2024

To the Annual General Meeting (AGM) on May 14, 2024, the Nomination Committee of Ependion AB has informed the company that it will be proposing following:· that the Board of Directors shall consist of five members. · re-election of Board members Johan Wester, Karin Gunnarsson, Lars Eklöf and Jonas Hård. Bo Elisson has declined re-election. Charlott Samuelsson has, for personal reasons, also declined re-election. · new election of Peter Nilsson. · election of Peter Nilsson as Chairman of the Board. · election of Bo Elisson as the Chairman of the Meeting.    Peter Nilsson,

Australia’s Intermodal Terminal Company orders seven electric Konecranes RMG cranes for new Melbourne freight facility

Intermodal Terminal Company (ITC) has ordered seven Konecranes Rail Mounted Gantry (RMG) cranes for its new Somerton terminal in north Melbourne, Australia, to support its ambitious national growth plans. The delivery also includes seven Konecranes Remote Operating Stations (ROSs). Delivery will take place between April and September 2025. The order was booked in December 2023. Wholly owned and backed by Aware Super, one of Australia’s leading superannuation funds managing $170 billion on behalf of its 1.1 million members, the ITC aims to assemble a national portfolio of terminals with

Mandatum plc: Managers' Transactions (Lapveteläinen)

Mandatum plc, Stock exchange release / Managers’ transactions, 16 of February 2024 at 10:00 a.m. EET Mandatum Oyj - Managers' Transactions – Lapveteläinen Mandatum plc (Business ID 3355142-3) has received the following notification under Article 19 of the Market Abuse Regulation. Shares have been acquired in accordance with the demerger plan approved by Sampo plc’s Annual General Meeting on 17 May 2023. _________________________________ Person subject to the notification requirement Name: Patrick Lapveteläinen Position: Member of the Board/Deputy member Issuer: Mandatum

Mandatum plc: Managers' Transactions (Laaksonen)

Mandatum plc, Stock exchange release / Managers’ transactions, 16 of February 2024 at 10:00 a.m. EST Mandatum Oyj - Managers' Transactions – Laaksonen Mandatum plc (Business ID 3355142-3) has received the following notification under Article 19 of the Market Abuse Regulation. Shares have been acquired in accordance with the demerger plan approved by Sampo plc’s Annual General Meeting on 17 May 2023. _________________________________ Person subject to the notification requirement Name: Kimmo Laaksonen Position: Member of the Board/Deputy member Issuer: Mandatum Oyj

Mandatum plc: Managers' Transactions (Fagerholm)

Mandatum plc, Stock exchange release / Managers’ transactions, 16 of February 2024 at 10:00 a.m. EET Mandatum Oyj - Managers' Transactions – Fagerholm Mandatum plc (Business ID 3355142-3) has received the following notification under Article 19 of the Market Abuse Regulation. Shares have been acquired in accordance with the demerger plan approved by Sampo plc’s Annual General Meeting on 17 May 2023. _________________________________ Person subject to the notification requirement Name: Jannica Fagerholm Position: Member of the Board/Deputy member Issuer: Mandatum Oyj

Publication of Solwers' Financial Statements 2023 Release and invitation to webcast

Solwers Plc Press release 16 February 2024 at 10:00 am EEST Solwers will publish its Financial Statements Release for January–December 2023 on Wednesday, 28 February, approximately at 09.00 am EEST. When published, the Financial Statements Release will be available in Finnish and English on the company’s website at www.solwers.com. CEO Stefan Nyström and CFO Teemu Kraus will present the company’s result in a live English webcast on the same day, starting at 10:00 am EEST. The webcast can be followed by registering at https://solwers.videosync.fi/financial-statement-release2023/

Qlife reports first milestone achieved and on track with Chinese collaboration

UPDATE: Qlife has previously reported the potential of its Chinese collaboration and is now updating accordingly: Qlife’s collaboration with Hipro Biotechnology to bring home-hospital blood biomarker testing into the Chinese market and elsewhere – is progressing according to plan and has been further expanded with a focus on additional biomarker tests.The collaboration consists of four major parts: 1. Integration of reagents 2. Regulatory approval in China 3. Distribution and sales in China 4. Production of Egoo in China Integration of reagents The parties have worked

Mandatum plc: Managers' Transactions (Ruuska)

Mandatum plc, Stock exchange release / Managers’ transactions, 16 of February 2024 at 10:00 a.m. EST Mandatum Oyj - Managers' Transactions – Ruuska Mandatum plc (Business ID 3355142-3) has received the following notification under Article 19 of the Market Abuse Regulation. Shares have been acquired in accordance with the demerger plan approved by Sampo plc’s Annual General Meeting on 17 May 2023. _________________________________ Person subject to the notification requirement Name: Jukka Ruuska Position: Member of the Board/Deputy member Issuer: Mandatum Oyj LEI:

Mandatum plc: Managers' Transactions (Aho)

Mandatum plc, Stock exchange release / Managers’ transactions, 16 of February 2024 at 10:00 a.m. EST Mandatum Oyj - Managers' Transactions – Aho Mandatum plc (Business ID 3355142-3) has received the following notification under Article 19 of the Market Abuse Regulation. Shares have been acquired in accordance with the demerger plan approved by Sampo plc’s Annual General Meeting on 17 May 2023. _________________________________ Person subject to the notification requirement Name: Markus Aho Position: Member of the Board/Deputy member Issuer: Mandatum Oyj LEI:

Mandatum plc: Managers' Transactions (Lamminen)

Mandatum plc, Stock exchange release / Managers’ transactions, 16 of February 2024 at 10:00 a.m. EET Mandatum Oyj - Managers' Transactions – Lamminen Mandatum plc (Business ID 3355142-3) has received the following notification under Article 19 of the Market Abuse Regulation. Shares have been acquired in accordance with the demerger plan approved by Sampo plc’s Annual General Meeting on 17 May 2023. _________________________________ Person subject to the notification requirement Name: Johanna Lamminen Position: Member of the Board/Deputy member Issuer: Mandatum Oyj

Ericsson to utilize mandate to transfer shares

Ericsson’s (NASDAQ:ERIC) annual general meeting on March 29, 2023 authorized the company’s board of directors to resolve on the transfer of the company’s own shares. Under the authorization the company may, in conjunction with the delivery of vested shares under the long-term variable compensation programs 2019 and 2020 (“LTV 2019” and “LTV 2020”), prior to the annual general meeting in 2024, decide to retain and sell no more than 60% of the vested shares of series B in the company in order to cover for the costs for withholding and paying tax and social security liabilities on behalf of

Enzymatica’s rights issue is secured to 100 percent

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, SINGAPORE THE UNITED STATES OF AMERICA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR INVOLVE REQUIREMENTS FOR MEASURES OTHER THAN WHAT FOLLOWS BY SWEDISH LAW. The Board of Directors of Enzymatica AB (publ) (”Enzymatica” or ”the Company”) decided on February 16, 2024, to carry out a rights issue of SEK 27.4 million with preferential rights for existing shareholders. The Board of

Bio-Works expands product range with introduction of WorkBeads 40 Butyl SH

WorkBeads 40 Butyl SH is a pioneering hydrophobic interaction chromatography (HIC) resin for purification of plasmids, proteins, peptides, and oligonucleotidesToday, Bio-Works, a trailblazer in purification solutions, is thrilled to announce the addition of WorkBeads™ 40 Butyl SH to its product portfolio. This revolutionary hydrophobic interaction chromatography (HIC) resin is designed for research and industrial-scale purification of proteins, peptides, plasmids, and oligonucleotides. This launch marks a significant expansion of Bio-Works' product range. Advantages of WorkBeads 40 Butyl

AutoStore Holdings Ltd. - Mandatory notification of trade

(Nedre Vats, 16 February 2024): With reference to the stock exchange announcement made earlier today, AutoStore Holdings Ltd. ("AutoStore") has been notified of PDMR trades made by funds associated with Thomas H. Lee Partners LP ("THL"). THL is represented on the board of directors of AutoStore and are considered as closely associated with James C. Carlisle (chair of the AutoStore board of directors) and Michael M. Kaczmarek (AutoStore board member). Notifications for transactions by close associates are enclosed to this announcement. This information is subject to the disclosure

Rightbridge Ventures and its subsidiary 1337 esports AB partners with Adventure Box to boost Kogama platform growth

Rightbridge Ventures Group AB (Publ) (“Rightbridge Ventures” or “Rightbridge”) has through its wholly owned subsidiary 1337 esports AB (“1337”) entered into a strategic partnership and consultancy agreement with Adventure Box Technology AB (“Adventure Box”), the company behind the popular social gaming platform Kogama. 1337 is appointed with the goal to accelerate Kogama's growth by structuring its media offering and creating new revenue opportunities and opportunities within the Rightbridge ecosystem. The agreement consists of a fixed fee for 1337 and a variable performance based fee.

Cereno Scientific releases Insights Videos Season 3 Episode 1–4 with Sten R. Sörensen, CEO, Cereno Scientific

Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that episodes 1- 4 of Season 3 in the Insights Video Series has been released. In the videos, recorded at the Pulmonary Vascular Research Institute (PVRI) Annual Congress 2024, CEO Sten R. Sörensen highlights the remarkable early signs of efficacy in Cereno Scientific’s Phase II study with candidate drug CS1 in patients with PAH, the importance of the “Compassionate Use”-approval for CS1 by the FDA, the potential of HDAC inhibition by CS1 and

Year-end bulletin Pharmacolog 2023

Press release: Uppsala, February 16, 2024 Pharmacolog i Uppsala AB (publ) year-end bulletin for the period January - December 2023 is now available on the company's website  and is attached as a pdf.Fourth quarter October 1 - December 31, 2023 · The Group's net sales for the fourth quarter amounted to KSEK 2 567 (1 785). · Operating profit for the quarter amounted to KSEK -4,159 (-6,763). · Net earnings per share for the quarter were SEK -0.06 (-0.36) before dilution and SEK -0.03 (-0.31) after dilution. The

Repurchase of Outokumpu’s own shares

Outokumpu OyjStock exchange releaseFebruary 16, 2024 at 9.30 am EETRepurchase of Outokumpu’s own shares On February 15, 2024, Outokumpu has completed repurchases of its own shares as follows (ISIN FI0009002422): +-------+----------------+------------------------------------+----------------+|Trading|Number of shares|Weighted average price / share, EUR*|Total cost, EUR*||venue | | | |+-------+----------------+------------------------------------+----------------+|CEUX |17,167 |4.1134

Year-end report 2023: Scientific and regulatory progress generating international interest

Fourth quarter January-December · Net sales reached SEK · Net sales reached SEK 50.9 (48.9)15.8 (16.6) million. million. · The operating result · The operating result totaled SEK -48.1 (totaled SEK -13.8 (-21.6) -68.2) million.million. · Earnings per share, basic and diluted, · Earnings per share, basic wereand diluted, were SEK -0.30 (-0.44).SEK -0.09 (-0.14). · Cash flow from operating activities for · Cash flow from operating the period totaled SEK -40.3 (-65.4)

Elicera invites to investor meetings on February 28[th] and 29[th] 2024

In connection with the upcoming rights issue in Elicera Therapeutics AB (publ) ("Elicera" or "the Company"), the Company invites shareholders and the public to an investor meeting in Stockholm and a digital investor meeting.Elicera's CEO, Jamal El-Mosleh, will present the Company on two occasions. The first occasion is on Wednesday, February 28th, at 4:00 PM and will be held digitally via Microsoft Teams. The second occasion is on Thursday, February 29th, at 12:00 PM and will be held at Mangold Fondkommission’s premises at Nybrogatan 55, where lunch will also be provided. Do note that both

There are no items matching the current filter
There are no more items matching the current filter
Back to top